December 20, 2016
December 20, 2016 (Coralville, IA) – Viewpoint Molecular Targeting, LLC has been selected by the National Cancer Institute (NCI) to participate in the business accelerator program I-Corps in 2017.
The I-Corps program was developed by the National Science Foundation and adopted by select NIH institutes, including the NCI. The program helps SBIR funded companies accelerate the development and commercialization of new products and services that benefit society. This is achieved through an 8-week training program designed to provide scientists real world, hands-on entrepreneurial training, facilitated by experts in the biotech sector. Participants are selected by a competitive application process to receive grant support for the entrepreneurial training, mentorship, and collaborations that will assist them in translating research ideas into market ready products. The program kicks off with a 3-day workshop in Boston (MA) in early February. “This is an intense program that will no doubt help us to validate our business model assumptions and accelerate Viewpoint’s growth.” Says Viewpoint CEO Heyward Coleman. “We are geared up for an enthusiastic participation”.
Viewpoint, located in the UI BioVentures Center (Coralville, IA), is developing pharmaceutical drugs for therapy and diagnostic imaging of cancer, with a focus on metastatic melanoma. Viewpoint has secured over $1.2M in external funding; more than half of this amount has come from NIH SBIR grants and contracts. The company is poised to begin clinical testing for its lead product and has other products in the development pipeline.
“Our technology has the potential to save lives” says Co-founder and Chief Medical Officer Frances Johnson. “The NCI’s selection of Viewpoint to participate in the I-Corps program validates that potential and gives us another great opportunity to make targeted radiotherapy for melanoma a reality.”